Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
- Transaction Price: $47.03 per American Depositary Share (ADS).
- Transaction Date: February 19, 2015.
- Transaction Type: Increase in notional allocation of GSK ADSs within the GSK 401K plan following a cash element revaluation.
Material Changes
The filing reports an increase in notional ADS allocations for specific individuals due to the revaluation of the cash element within the company's 401K plan. No material changes to the company's overall financial position or operations are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific director transaction notification.
Key Facts for Investor Verification
- Verify the specific number of ADSs allocated to Mr. W C Louv (27), Dr. M M Slaoui (20), and Dr. K Slaoui (17).
- Confirm the transaction price of $47.03 per ADS on February 19, 2015.
- Note that these transactions were notional allocations resulting from a 401K plan revaluation, not open market purchases or sales.